Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m(2): Subgroup Analysis of the Randomized CREDENCE Trial

BACKGROUND AND OBJECTIVES: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidney failure and cardiovascular events in participant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin J Am Soc Nephrol
Hauptverfasser: Bakris, George, Oshima, Megumi, Mahaffey, Kenneth W., Agarwal, Rajiv, Cannon, Christopher P., Capuano, George, Charytan, David M., de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Heerspink, Hiddo J.L., Levin, Adeera, Neal, Bruce, Oh, Richard, Pollock, Carol, Rosenthal, Norman, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Jardine, Meg J., Perkovic, Vlado
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Nephrology 2020
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769025/
https://ncbi.nlm.nih.gov/pubmed/33214158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.10140620
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge